title: Simple enucleation versus radical nephrectomy in the treatment of pT1a and pT1b renal cell carcinoma.
abstract: BACKGROUND
  Simple tumor enucleation (TE) showed excellent oncologic results in large retrospective series. No study has compared oncologic outcomes after TE and radical nephrectomy (RN) for the treatment of pT1 renal cell carcinoma (RCC). The aim of the present study is to compare the oncologic outcomes after TE and RN in pT1 RCCs.
  
  
  METHODS
  We retrospectively analyzed 475 patients who underwent TE or RN for pT1 RCC, N0, M0, between 1995 and 2007. TE was performed in 332 patients and RN in 143. Local recurrence, progression-free survival (PFS), and cancer-specific survival (CSS) were the main outcomes of this study. The Kaplan-Meier method was used to calculate survival functions, and differences were assessed with the log rank statistic. Univariate and multivariate Cox regression models were also used.
  
  
  RESULTS
  The 5- and 10-year PFS estimates were 91.3 and 88.7% after RN and 95.3 and 92.8% after TE (P = NS), respectively. The 5- and 10-year CSS estimates were 92.1 and 89.4% after RN and 94.4% (5- and 10-year CSS) after TE (P = NS), respectively. No statistically significant differences between RN and TE were found after adjusting CSS probabilities according to age at surgery, grade, stage, or clear cell subtype. Surgical treatment was not a predictor of PFS or CSS by both univariate and multivariate analyses. The potential limitation of this study is that the data originate from a retrospective review.
  
  
  CONCLUSIONS
  TE can achieve oncologic results similar to those of RN for the treatment of pT1 RCCs, provided tumors are carefully selected on the basis of their safe and complete removal.
authors.affiliation: Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. andreamine@libero.it
authors.forename: Andrea
authors.initials: A
authors.lastname: Minervini
authors.forename: Sergio
authors.initials: S
authors.lastname: Serni
authors.forename: Agostino
authors.initials: A
authors.lastname: Tuccio
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Siena
authors.forename: Gianni
authors.initials: G
authors.lastname: Vittori
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Masieri
authors.forename: Saverio
authors.initials: S
authors.lastname: Giancane
authors.forename: Michele
authors.initials: M
authors.lastname: Lanciotti
authors.forename: Saba
authors.initials: S
authors.lastname: Khorrami
authors.forename: Alberto
authors.initials: A
authors.lastname: Lapini
authors.forename: Marco
authors.initials: M
authors.lastname: Carini
mesh_terms: D002291:Carcinoma, Papillary / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002467:Cell Nucleus / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009392:Nephrectomy; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate